Moving the Needle: Clinical Strategies focusing on Controlling LDL-C

In this episode of CardiaCast, Drs. Erin Michos and Joseph Saseen discuss the underuse of lipid-lowering therapies in patients with cardiovascular risk, despite strong evidence and updated guidelines. They highlight the role of bempedoic acid as a non-statin option, especially for statin-intolerant patients. The conversation emphasizes team-based care, shared decision-making, and strategies to navigate insurance barriers to improve LDL-C management. This podcast is part of Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape grant initiative. Educational grant support is provided by Esperion. Related References Nelson A, Haynes K, Shambhu S, et al. High-intensity statin use among patients with atherosclerosis in the U.S. J Am Coll Cardiol. 2022;79(18):1802–1813. doi:10.1016/j.jacc.2022.02.048 Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060–1068. doi:10.1001/jamacardio.2021.1810 Worledge EA, Billups SJ, Titus OJ, Saseen JJ. Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease. J Clin Lipidol. Published online April 11, 2025. doi:10.1016/j.jacl.2025.04.186 Subscribe to CardiaCast